Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based on SWIFT trials showing ...

Please provide your email address to receive an email when new articles are posted on . Depemokimab’s mechanism of action is similar to mepolizumab. Three adverse events led to discontinuation or ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR-1 and ...

Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, ...

Please provide your email address to receive an email when new articles are posted on . Depemokimab has high binding affinity and potency for IL-5. Eosinophils fell by 83% and 82% with treatment in ...

Depemokimab significantly reduces asthma exacerbations, showing similar efficacy in both controlled and uncontrolled asthma patients. The study included patients with eosinophilic asthma using medium- ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning that ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its own. The British Big Pharma has filed depemokimab for FDA approval in two ...

If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing Submissions based on data from positive SWIFT and ANCHOR trials SWIFT-1 and -2 showed depemokimab reduced ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two doses annually. Phase 3 trials demonstrated significant reductions in asthma ...